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Abstract. 
 
Transforming growth factor 
 
b
 
 (TGF-
 
b
 
) sig-
naling involves interactions of at least two different re-
ceptors, types I (T
 
b
 
RI) and II (T
 
b
 
RII), which form 
ligand-mediated heteromeric complexes. Although we 
have shown in the past that T
 
b
 
RII in the absence of 
ligand is a homodimer on the cell surface, T
 
b
 
RI has not 
been similarly investigated, and the site of complex for-
mation is not known for either receptor. Several studies 
have indicated that homomeric interactions are in-
volved in TGF-
 
b
 
 signaling and regulation, emphasizing 
the importance of a detailed understanding of the ho-
mooligomerization of T
 
b
 
RI or T
 
b
 
RII. Here we have 
combined complementary approaches to study these 
homomeric interactions in both naturally expressing 
cell lines and cells cotransfected with various combina-
tions of epitope-tagged type I or type II receptors. We 
used sedimentation velocity of metabolically labeled 
receptors on sucrose gradients to show that both T
 
b
 
RI 
and T
 
b
 
RII form homodimer-sized complexes in the 
endoplasmic reticulum, and we used coimmunoprecipi-
tation studies to demonstrate the existence of type I ho-
mooligomers. Using a technique based on antibody-
mediated immunofluorescence copatching of receptors 
carrying different epitope tags, we have demonstrated 
ligand-independent homodimers of T
 
b
 
RI on the sur-
face of live cells. Soluble forms of both receptors are se-
creted as monomers, indicating that the ectodomains 
are not sufficient to mediate homodimerization, al-
though TGF-
 
b
 
1 is able to promote dimerization of the 
type II receptor ectodomain. These findings may have 
important implications for the regulation of TGF-
 
b
 
 sig-
naling.
 
T
 
ransforming
 
 growth factor-
 
b
 
 (TGF-
 
b
 
)
 
1
 
 is a multi-
potent cytokine involved in a wide range of biologi-
cal functions including cell growth, apoptosis, pro-
duction of extracellular matrix, wound healing, and
differentiation (35, 37). Three high-affinity transmem-
brane receptors for TGF-
 
b
 
 were identified, first through
cross-linking of radiolabeled ligand and later by cDNA
cloning: the type I (T
 
b
 
RI, 55 kD), type II (T
 
b
 
RII, 75 kD),
and type III (280 kD) receptors (3, 9, 23, 25, 39). T
 
b
 
RI and
T
 
b
 
RII appear to be the signaling receptors, while the type
III receptor presents ligand to T
 
b
 
RII and I (21, 26, 29, 30,
44). T
 
b
 
RI and T
 
b
 
RII are serine-threonine kinases with
cysteine-rich extracellular domains and 41% identity be-
tween their kinase domains (9, 22, 24, 33). In the absence
of T
 
b
 
RI, the type II receptor can bind TGF-
 
b
 
 but does not
transduce signal (27, 43). On the other hand, T
 
b
 
RI can be
cross-linked to radiolabeled TGF-
 
b
 
 only in the presence of
T
 
b
 
RII (9, 13, 19, 43). The T
 
b
 
RII kinase is constitutively
active (23), and autophosphorylation on several serine res-
idues regulates its activity and interactions with T
 
b
 
RI (28).
The binding of TGF-
 
b
 
1 to T
 
b
 
RII mediates the formation
of a heteromeric complex of T
 
b
 
RI and T
 
b
 
RII and the
phosphorylation of specific serine residues in T
 
b
 
RI by
T
 
b
 
RII (36, 43, 44; Wells, R., L. Gilboa, Y. Henis, and H.
Lodish, manuscript in preparation). This phosphorylation
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1. 
 
Abbreviations used in this paper
 
: 
 
a
 
-HA, mouse monoclonal antibody
which recognizes a specific epitope of the HA protein; 
 
a
 
-myc, mouse
monoclonal antibody which recognizes a specific c-myc sequence; 
 
a
 
-IIC, a
polyclonal rabbit antiserum raised against the COOH-terminal 16 amino
acids of T
 
b
 
RII; I-SF, soluble HA-tagged T
 
b
 
RI ectodomain; II-SF, soluble
HA-tagged T
 
b
 
RII ectodomain; ECL, enhanced chemiluminescence;
Endo H, endoglycosidase H; Epo, erythropoietin; G
 
a
 
M, goat IgG anti–
mouse IgG; HA, influenza hemagglutinin; Octyl-POE, 
 
n
 
-octyl-polyoxy-
ethylene; TGF-
 
b
 
, transforming growth factor 
 
b
 
; T
 
b
 
RI, TGF-
 
b
 
 type I re-
ceptor; T
 
b
 
RII, TGF-
 
b
 
 type II receptor.
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activates T
 
b
 
RI kinase activity and promotes its interac-
tions with downstream effector molecules, including mem-
bers of the SMAD family (1, 2, 31, 32, 45).
Both the type II (6, 12) and the type III (12) TGF-
 
b
 
 re-
ceptors form ligand-independent homooligomers (proba-
bly dimers) on the cell surface. That this is functionally im-
portant for the type II receptor is shown by studies
demonstrating that homooligomerization of T
 
b
 
RII is in-
volved in both positive and negative regulation of signal
transduction via intermolecular autophosphorylation of
specific serine residues (28). So far, there is no direct phys-
ical evidence for T
 
b
 
RI homomeric complexes. Two lines
of evidence, however, suggest that the TGF-
 
b
 
 receptor sig-
naling complex contains at least two type I receptors: chi-
meric proteins with the extracellular domain of the eryth-
ropoietin (Epo) receptor and the cytoplasmic domain of a
constitutively active T
 
b
 
RI mutant are not active unless
dimerized by Epo (27), and functionally complementary
T
 
b
 
RI mutants falling into two classes, termed kinase de-
fective and activation defective, have been isolated (40).
We report here a detailed investigation of T
 
b
 
RI and
T
 
b
 
RII homooligomer formation. We have studied cell
lines that express native TGF-
 
b
 
 receptors as well as cells
cotransfected with various combinations of epitope-tagged
receptors using several complementary approaches: su-
crose gradient velocity centrifugation to determine the
size of the receptor complexes, coimmunoprecipitation,
and immunofluorescence copatching studies to detect re-
ceptor oligomerization on the surface of live cells. We
show that both T
 
b
 
RI and T
 
b
 
RII form homodimers in the
ER and that the extracellular region alone is insufficient
for dimerization of either receptor. Our results further
demonstrate that, similar to the type II receptor (12),
T
 
b
 
RI forms ligand- and DTT-independent homooligo-
mers on the surface of live COS7 cells. These results have
important implications for our understanding of the events
involved in TGF-
 
b
 
 signaling.
 
Materials and Methods
 
Materials
 
TGF-
 
b
 
1 was supplied by Celltrix Laboratories (Palo Alto, CA) and R & D
Systems, Inc. (Minneapolis, MN) and was radioiodinated for affinity label-
ing of tagged receptors as described (34, 39). For affinity labeling of solu-
ble receptors, radioiodination was modified as described (41). 9E10
(
 
a
 
-myc) mouse ascites, which recognizes a specific c-myc sequence (8),
was purchased from Harvard Monoclonals (Boston, MA). 12CA5 (
 
a
 
-HA)
mouse ascites, which recognizes an epitope of the influenza hemagglutinin
(HA) protein (42), was from BAbCO (Richmond, CA). IgG fractions
were prepared from mouse ascites by ammonium sulfate precipitation fol-
lowed by DEAE-cellulose chromatography (10). F (ab
 
9
 
)
 
2
 
 fragments were
generated by pepsin digestion, following the protocol of Kurkela et al.
(18). Fluorophore-labeled affinity-purified antibodies and Cy3-streptavi-
din were obtained from Jackson ImmunoResearch Laboratories (West
Grove, PA). All the F (ab
 
9
 
)
 
2
 
 preparations were reduced by mercaptoetha-
nol and alkylated with iodoacetamide to generate monovalent Fab
 
9
 
 frag-
ments (11). To eliminate possible traces of IgG, the Fab
 
9
 
 preparations
were treated with protein A–Sepharose (for 12CA5 or goat IgG) or pro-
tein G–Sepharose (for 9E10 IgG). The resulting Fab
 
9
 
 were free of con-
tamination by F (ab
 
9
 
)
 
2
 
 or IgG, as judged by SDS-PAGE under nonreduc-
ing conditions.
 
Cell Lines
 
COS7 and L6 cells (CRL 1651 and CRL 1458, respectively; American
 
Type Culture Collection, Rockville, MD) were grown in DME supple-
mented with 10% FCS (Biological Industries, Beit Haemek, Israel or
GIBCO-BRL, Gaithersburg, MD), 100 U/ml penicillin, 100 
 
m
 
g/ml strepto-
mycin, and 4 mM glutamine (Biological Industries or JRH Biosciences,
Lenexa, KS).
 
Epitope Tagging of T
 
b
 
RI
 
Epitope tagging was performed according to Kolodziej and Young (16)
using site-directed mutagenesis on uracil-containing single-stranded phage-
mids (17). The human TGF-
 
b
 
RI (ALK5) cDNA (9) was inserted into the
SV-40 expression vector pcDNA-I (Invitrogen Corp., Carlsbad, CA) via
HindIII and NotI sites on the polylinker. Using this vector, which also car-
ries an M13 origin of replication, single-stranded phagemids were grown
in a dut
 
2
 
 ung
 
2
 
 
 
Escherichia coli
 
 strain (CJ236/P3; Invitrogen Corp.) with
M13K07 (Bio-Rad Laboratories, Hercules, CA) as helper phage. Site-
directed mutagenesis on this template was performed with mutagenic oli-
gonucleotides encoding the epitope-tag sequence flanked by the se-
quences corresponding to nucleotides 66–81 (on the 5
 
9
 
 end) and 82–97
(3
 
9
 
 end) of the human T
 
b
 
RI (counting the A of the methionine codon of
the cDNA as 1). The tag sequences used encoded either the HA epitope
YPYDVPDYA or the human c-myc epitope EQKLISEEDL. Each tag
was inserted in-frame, nine bases downstream of the putative signal pep-
tide sequence. Double-stranded pcDNA-I preparations with inserts of
wild-type T
 
b
 
RI or the epitope-tagged receptors were digested by XbaI,
cutting in two places (at the 3
 
9
 
 of the polylinker and at position 706 in the
T
 
b
 
RI coding sequence). The 1.6-kb piece from the wild-type, untagged re-
ceptor encoding most of the coding region of the cDNA was ligated with
the 4.9-kb piece from the myc- or HA-tagged NH
 
 2
 
-terminal T
 
b
 
RI se-
quences and the cloning vector pcDNA-I. The resulting constructs con-
tained as insert all of the T
 
b
 
RI coding region, most of which was derived
from the wild-type, untagged receptor clone, and the NH
 
 2
 
-terminal region
(including the tag) derived from the tagged receptor clone. The coding re-
gions derived from the tagged cDNAs were verified by DNA sequencing.
 
Construction of HA-tagged Soluble Receptors
 
To construct an HA-tagged secreted form of the T
 
b
 
RII ectodomain (II-
SF), a HindIII-PstI fragment of the full-length HA-tagged T
 
b
 
RII (T
 
b
 
RII-
HA; 12) containing the 5
 
9
 
 region of the ectodomain was ligated into a
PstI-HindIII fragment of the type II–secreted receptor (containing the 3
 
9
 
region of the ectodomain) in pcDNA-I (24). For the experiments below,
the construct was moved into the vector pcDNA-I/Amp (Invitrogen
Corp.) via the HindIII-XbaI sites of the multiple cloning region.
A secreted form of T
 
b
 
RI was constructed by using PCR to insert a stop
codon at the 5
 
9
 
 end of the transmembrane domain, just upstream of a
PvuII site, replacing Leu
 
126
 
. The mutated cDNA was then cut with EcoRI
(at the insertion site on the 5
 
9
 
 end) and PvuII and was inserted into the
EcoRI and EcoRV sites of pcDNA-I/Amp (untagged I-SF). The HA-
tagged full-length receptor was cut with HindIII (in the vector) and XhoI
(cuts in the ectodomain sequences). The fragment containing the HA-tag
was inserted into a backbone of the untagged I-SF cut with HindIII and
XhoI (partial digest, with cut in the ectodomain), to yield the HA-tagged
secreted form of T
 
b
 
RI (I-SF). The sequence in regions derived from PCR
amplification was confirmed by sequencing.
 
COS7 Cell Transfections
 
COS7 cells were transiently transfected by the DEAE-dextran method
(38) using pcDNA-I or pcDNA-I/Amp containing the T
 
b
 
RI and T
 
b
 
RII
constructs (tagged, untagged, or the tagged soluble receptors). Cells were
used for experiments 48 h after transfection.
 
Metabolic Labeling
 
Cells were grown to subconfluence in standard media on 10 cm plates.
They were rinsed once with PBS, then starved in serum-free DME minus
methionine and cysteine (ICN Biomedicals, Costa Mesa, CA) for 3–4 h at
37
 
8C. The medium was replaced with fresh starvation medium supple-
mented with 0.2 mM oxidized glutathione (Boehringer Mannheim Corp.,
Indianapolis, IN) and 0.5 mCi/ml of [35S]methionine and [35S]cysteine (Ex-
press; New England Nuclear, Beverly, MA) and incubated at 378C for 15
or 30 min. Plates were then rinsed three times with ice-cold PBS and incu-
bated in 0.2 M iodoacetamide (1 M stock solution in 0.5 M Tris-HCl, pH
8.8, diluted to 0.2 M in PBS) for 10 min at 48C. Cells were transferred into
Eppendorf tubes (Madison, WI), lysed in 150 ml of MNT buffer (20 mMGilboa et al. Homodimerization of Types I and II TGF-b Receptors 769
MES pH 6.0, 30 mM Tris, pH 7.4, 100 mM NaCl) supplemented with 2%
n-octyl-polyoxyethylene (octyl-POE; Bachem Biosciences, Philadelphia,
PA), and cleared with a 10–15-min spin (14,000 g) at 48C. “1SDS” sam-
ples were lysed in MNT lysis buffer with 0.5% SDS. The HA-tagged se-
creted receptors (II-SF and I-SF) were metabolically labeled by rinsing
transfected COS7 cells with PBS, followed by incubating the cells in 6 ml/
10-cm dish of starvation medium with oxidized glutathione and 0.1 mCi/ml
35S-Express for 10.5 h. Media from two plates were then collected, filtered
with a 0.22-mm filter, brought to 20 mM Hepes, pH 7.5, and 1 mM PMSF,
concentrated in a Centricon 10 concentrator (Amicon, Inc., Berverly,
MA) rinsed several times with MNT, brought to 150 ml with MNT (no de-
tergent), and loaded on gradients as below.
Velocity Sedimentation on Sucrose Gradients
50 ml of size markers—carbonic anhydrase (29 kD), BSA (66 kD), alcohol
dehydrogenase (150 kD), b-amylase (200 kD), apoferritin (443 kD), and
thyroglobulin (669 kD), each 9 mg/ml except apoferritin, which was 2.2
mg/ml (Sigma Chemical Co., St. Louis, MO)—in MNT lysis buffer were
added to the 150-ml lysates described above and layered over 4.0-ml gradi-
ents of 7.5–30% sucrose in MNT/1% octyl-POE. 1SDS samples included
an additional 0.5% SDS added to each gradient. Gradients were centri-
fuged in an SW60 rotor (Beckman Instruments, Fullerton, CA) at 60,000
rpm for 8 h at 48C. 250-ml fractions were removed sequentially from the
top of each gradient using a hand-held pipettor. To analyze size standards,
25-ml aliquots were removed from each fraction and were separated by
8–15% gradient SDS-PAGE, followed by Coomassie blue staining. The
remainder of each fraction was brought to 0.5 ml (1 ml for 1SDS samples)
with IP buffer (0.5% deoxycholate, 1% Triton X-100, 10 mM EDTA, in
PBS, pH 8.0) and immunoprecipitated with (a) 10 ml/ml of a polyclonal
rabbit antiserum raised against the COOH-terminal 16 amino acids of
TbRII (a-IIC; reference 36); (b) 15 ml/ml of a polyclonal rabbit antiserum
raised against the juxtamembrane cytoplasmic domain of TbRI (9); or (c)
1 ml/ml a-HA ascites. After overnight incubation at 48C, 50 ml of protein
A–Sepharose CL-4B beads (1:1 in PBS; Sigma Chemical Co.) were added,
and the lysates were incubated with rotation for an additional 30 min.
Beads were rinsed twice with IP buffer (with 0.5% SDS for type II recep-
tor immunoprecipitations) and once with PBS and eluted by boiling in
SDS-PAGE sample buffer. Control immunoprecipitants (from lysates
treated identically, but not run on gradients) were eluted into 0.5% SDS
and one half of each was digested overnight at 378C with endoglycosidase
H (Endo H; Genzyme Corp., Boston, MA; 100 mIU/ml) in the presence of
100 mM sodium citrate, pH 6. Samples were analyzed by 7.5% SDS-
PAGE; gels were fluorographed with 2,5 diphenyl-oxazole, dried, and
placed on Kodak XAR film (Rochester, NY), which was quantitated with
a LaCie Silverscanner II and MacBAS (Fuji Photo Film Co., Tokyo, Ja-
pan) software. The secreted receptors in the media collected from the cells
(see former section) were treated similarly, except that the gradients were
5–15% sucrose in MNT without detergent, and markers were cytochrome
C (12.4 kD), carbonic anhydrase (29 kD), and BSA (66 kD). Fractions
from the sucrose gradients were brought to 750 ml with IP buffer, immu-
noprecipitated with a-HA, and analyzed on 15% polyacrylamide/1.2%
bisacrylamide SDS gels.
Receptor Cross-Linking
Binding and cross-linking of 100 pM 125I–TGF-b1 to transfected COS7
cells grown on 10-cm dishes was as described (36). Cross-linked proteins
were resolved by 7.5% SDS-PAGE under reducing conditions and ex-
posed to Kodak XAR film at -708C. For affinity labeling of II-SF, trans-
fected COS7 cells were rinsed with PBS and incubated at 378C for 10.5 h
in 6 ml/10-cm dish of DME without serum. The media from two dishes
were filtered and concentrated as for the metabolically labeled material,
brought to 1.0 ml with KRH (50 mM Hepes, pH 7.5, 128 mM NaCl, 1.3 mM
CaCl2, 5 mM MgSO4, 5 mM KCl), and incubated for 3.5 h at 48C with 250
pM 125I–TGF-b1. Disuccinimidyl suberate (0.1 mg/ml) was added (48C, 15
min). The resulting material was quick-spun to remove insoluble cross-
linker, concentrated with several washes of MNT, and brought up to 150
ml with MNT (no detergent) before being loaded on a 5–15% sucrose gra-
dient.
Receptor Coimmunoprecipitation
48 h after transfection, cells were washed and incubated with serum-free
medium (30 min, 378C) to eliminate residual ligand. 2 mM DTT was
added for the last 10 min of the incubation to selected dishes. Cells were
then washed twice in ice-cold HBSS/Hepes/BSA (Hanks’ balanced salt so-
lution with 20 mM Hepes, pH 7.4, supplemented with 1% fatty acid–free
BSA; Sigma Chemical Co.) and incubated in the same medium with or
without 250 pM TGF-b1 (48C, 1.5 h). The cells were washed twice more in
HBSS/Hepes and lysed in a lysis buffer (PBS containing 1% Triton X-100,
10 mM EDTA, 1 mM p-aminoethylbenzenesulfonyl fluoride). Extracts
were precleared (48C, 1 h) by incubation with protein A–Sepharose (Phar-
macia Biotech, Piscataway, NJ) for immunoprecipitation with 12CA5 an-
tibodies or with protein G-Sepharose (for immunoprecipitation with 9E10
antibodies). Immunoprecipitation was carried out (48C, 2 h) with 20 mg/ml
of the appropriate IgG together with protein A– or protein G–Sepharose.
Immunoprecipitates were washed three times with the lysis buffer, dis-
solved in Laemmli loading buffer with or without mercaptoethanol, and
run on 7% SDS-PAGE. For N-glycosidase F treatment, immunoprecipi-
tates were dissolved in 20 ml 0.5% SDS. 20 ml of 23 enzyme buffer (100
mM sodium phosphate, pH 7.5, 2% NP-40), and 2 U of N-glycosidase F
(Boehringer Mannheim Corp.) was added to the eluate (378C, 4 h). The
gel was blotted onto nitrocellulose and then blocked in TBST (50 mM
Tris, 100 mM NaCl, 0.1% Tween 20, pH 7.4) with 2% BSA and 5% skim
milk (48C, 1 h). The blot was then sequentially incubated with 20 mg/ml
a-myc, 1:2,000 biotinylated GaM (goat IgG anti–mouse IgG; Jackson Im-
munoResearch Laboratories), and 1:1,000 streptavidin-horseradish perox-
idase (GIBCO-BRL). After each incubation, the blot was washed three
times in TBST (48C, 10 min). Enhanced chemiluminescence was used to
visualize the precipitated receptors by autoradiography on an x-ray film.
Immunofluorescence Copatching Experiments
The method used is based on Henis et al. (12), labeling the first epitope
with monovalent Fab9 fragments (to avoid adsorption of the mouse anti-
bodies against the second tag to secondary antibodies prebound to the
first tag). The method was modified by the use of a biotinylated secondary
Fab9 followed by Cy3-streptavidin to mediate patching of the first epitope
as well.
COS7 cells were grown on coverslips and transfected with TbRI-HA
and TbRI-myc constructs. 48 h after transfection, cells were washed twice
with serum-free DME and incubated 30 min at 378C to allow endocytosis
of ligand-bound receptors. After washing twice with cold HBSS/Hepes/
BSA, the cells were incubated in the same buffer (48C, 2 h) with normal
goat IgG (200 mg/ml) to block nonspecific binding. This was followed by
successive incubations (48C, 1 h each, with three washes between incuba-
tions) with: (a) a-myc Fab9(50 mg/ml); (b) Fab9 fragments of biotinylated
GaM (5 mg/ml); (c) Fab9 of unlabeled GaM (200 mg/ml), used to block all
free binding epitopes on the a-myc antibody; and (d) a-HA IgG (20 mg/ml);
(e) FITC-labeled GaM (20 mg/ml). The cells were then washed and fixed
by two incubations (15 min, 48C and then 15 min, 228C) with 3.2% para-
formaldehyde in PBS, pH 7.4, supplemented with 1.1% lysine and 0.24%
NaIO4. The reaction was quenched by three incubations with 50 mM gly-
cine in PBS, pH 7.4 (5 min, 228C). Cells were then incubated with 0.5 mg/ml
Cy3-streptavidin and mounted with mowiol (Hoechst AG, Frankfurt,
Germany) containing 29 mM n-propyl gallate (Sigma Chemical Co.). Flu-
orescence digital images were acquired with a Zeiss Axioskop (633 oil
objective; Thornwood, NY), coupled to a cooled CCD camera (model
CC/CE 200; Photometrics, Tuscon, AZ). The computerized microscope
system (15) and Priism software driving the focus, excitation, and emission
filter wheels were described earlier (5, 14). Fluorescein and Cy3 images
were taken using selective filter sets that essentially eliminate leakage. Su-
perposition of the two images and contrast enhancement were performed
after correction for shift and magnification using Priism interactive multi-
color visualization (5). The images were exported in TIFF format to Pho-
toshop (Adobe, San Jose, CA) and printed. 
Results
TbRI Forms Homodimers in the ER
Two different experiments in the literature have provided
functional evidence that TbRI forms homooligomers
within the signaling complex and that this oligomerization
is functionally relevant (27, 40). The oligomeric structure
of TbRI either in the ER or the plasma membrane has not
been thoroughly characterized, however, and there is noThe Journal of Cell Biology, Volume 140, 1998 770
conclusive evidence for physical interactions between
TbRI polypeptides in the absence of ligand and the type II
receptor. We therefore used sucrose gradient velocity cen-
trifugation of metabolically labeled receptors to determine
relative complex size. This approach was chosen since
chemical cross-linking of TbRI and TbRII has not been
possible (data not shown). We used L6 rat myoblasts,
which are TGF-b responsive and which express both of
the signaling receptors but lack the type III TGF-b recep-
tor that may form complexes with TbRI and TbRII and
could therefore complicate size determinations. L6 cells
were pulse-labeled for 30 min, conditions under which all
labeled TbRI is Endo H sensitive (41; Fig. 1 B). Endo H
sensitivity was used as a marker for localization in the ER
since only proteins in the ER and early Golgi carry the
high mannose sugars, which are susceptible to the enzyme.
Labeled L6 cells were lysed in a buffer containing octyl-
POE and analyzed by velocity sedimentation on sucrose
gradients in the same detergent, with or without SDS (see
Materials and Methods). Octyl-POE was chosen as the de-
tergent for several reasons: (a) It is nonionic; (b) it has a
density of 1; (c) it has a high CMC; and (d) it is freely mis-
cible in aqueous solutions, enabling analysis of the migra-
tion of detergent-solubilized proteins rather than of mi-
celles.
Receptors from cells lysed and run in the presence of
0.5% SDS yielded a peak at fractions 4–5, corresponding
to 50 kD, as determined by size marker analysis carried
out for each individual gradient (Fig. 1, A and C). This is
compatible with the molecular mass of the monomeric re-
ceptor, predicted to be 53 kD. Receptors from cells not
treated with SDS migrated with a peak in fractions 6–8
(Fig. 1, B and C), consistent with a size of 120 kD. Al-
though absolute size determinations from a gradient can
be inaccurate for detergent-solubilized membrane pro-
teins, the size of this complex compared with the SDS-
treated monomers is consistent with TbRI dimers. TbRI
from cells labeled similarly but chased for 4 h (such that la-
beled TbRI carried mature N-linked oligosaccharides and
was at the trans-Golgi or beyond; reference 41) migrated
with similar velocity. We conclude that TbRI forms dimer-
sized complexes in the ER. Similar results were obtained
with Mv1Lu cells (not shown) and with COS7 cells trans-
fected with tagged or untagged TbRI (Fig. 2 and data not
shown), demonstrating the generality of TbRI dimeriza-
tion. The similarity between COS7 cells and the naturally
expressing cell lines regarding TbRI dimerization indi-
cates that overexpression in COS cells does not affect
dimerization. This allowed us to use COS7 cells for immu-
nofluorescence copatching studies, which require receptor
density at the cell surface high enough to be visualized by
immunofluorescence.
Coimmunoprecipitation Studies Identify Ligand- and 
DTT-independent TbRI Homooligomers
The velocity sedimentation experiments described above
demonstrate that TbRI forms complexes of a size ex-
pected for a dimer. However, it is also possible that TbRI
associates with another protein of roughly the same size.
To demonstrate that TbRI indeed forms homooligomers,
we performed coimmunoprecipitation studies on cells
cotransfected with two TbRI forms, each carrying a differ-
ent epitope tag. HA or myc epitopes were inserted at the
ectodomain NH2 terminus, three amino acids downstream
of the putative signal sequence cleavage site. They were
introduced at the NH2 terminus to enable immunofluores-
cence copatching studies (see next section). Fig. 3 demon-
strates that the tagged receptors were expressed at the sur-
face of COS7 cells and labeled by 125I–TGF-b1 similar to
untagged TbRI. Very low levels of TbRI and TbRII were
observed in control cells transfected with vector alone
(Fig. 3, lane 5) or with TbRI cDNA in the same vector
(lane 4). These low levels may be attributed to the native
Figure 1. The type I receptor forms homodimers in the ER of L6
cells. L6 cells were pulse-labeled with 35S-Express for 30 min,
cooled, and derivatized with iodoacetamide. After lysis in MNT
buffer containing octyl-POE (with or without 0.5% SDS), sam-
ples were centrifuged on sucrose gradients, and the collected
fractions (numbered 1 to 15, with 1 at the top of the gradient)
were analyzed by immunoprecipitation with anti-TbRI antibod-
ies followed by SDS-PAGE and autoradiography (see Materials
and Methods). Endo H treatment (not shown) of control material
confirms that all of the labeled material is Endo H sensitive, rep-
resenting the ER form. (A) SDS (0.5%) was included in the lysis
buffer and in the gradient. Migration of the receptor is consistent
with monomers. (B) SDS was not present. Samples were treated
with Endo H before SDS-PAGE. Migration of the receptor is
consistent with dimers. (C) Graphical representation of the quan-
tified bands. Values were normalized to the peak fraction. Num-
bers at the top represent the protein size predicted by markers to
migrate at each peak.Gilboa et al. Homodimerization of Types I and II TGF-b Receptors 771
receptor population in COS7 cells. Cotransfection of
TbRI (tagged or untagged) together with TbRII resulted
in a significant increase in the labeling of TbRI (lanes 1–3).
The insertion of the epitope tags did not eliminate recep-
tor signaling, as tested by cotransfection with p3TP-Lux (a
construct that carries the luciferase gene under a TGF-b
response element) into L17 cells that lack endogenous
TbRI activity (not shown). Furthermore, in the sedimen-
tation velocity studies (Fig. 2), the tagged TbRI was able
to form dimer-sized complexes, as observed for the un-
tagged receptor.
We used the tagged type I receptors in coimmunopre-
cipitation experiments designed to confirm that the dimer-
sized TbRI complexes observed in the sedimentation ve-
locity studies did in fact represent dimers and to determine
whether exposure to ligand or DTT influence TbRI ho-
mooligomers. The latter experiment was motivated by the
observation that cross-linking of iodinated TGF-b1 to
TbRI in the presence of TbRII is eliminated by pretreat-
ment of cells with DTT (4), an effect that may involve dis-
ruption of the TbRI/TbRII heterooligomeric structure
(Rodriguez, C., R. Lin, P.E. Scherer, and H.F. Lodish,
manuscript in preparation). 
COS7 cells were cotransfected with TbRI-HA and
TbRI-myc and lysates were immunoprecipitated with a-HA
antibodies. The immunoprecipitates were subjected to
SDS-PAGE and Western blotting, and the blots were ana-
lyzed with a-myc antibodies followed by biotinylated
GaM and streptavidin–horseradish peroxidase. The re-
sults show that TbRI-myc coprecipitates with TbRI-HA
(Fig. 4 A, lane 5, and B, lane 2). Preincubation of cells with
TGF-b1 (Fig 4 A, lane 6, and B, lane 3), DTT (Fig 4 A,
lane 7), or both (lane 8) did not change the quantity of
TbRI-myc coprecipitated with TbRI-HA. Blots from con-
trol cells, singly transfected with TbRI-HA, were not
stained by a-myc, showing the specificity of the blotting
antibody (Fig. 4 A, lane 4). Transfection with TbRI-myc
alone was used as control for the immunoprecipitating an-
tibody, a-HA (Fig. 4 A, lane 3). A positive control of cells
singly expressing TbRI-myc, where a-myc was used both
Figure 2. TbRI forms ho-
modimers in the ER of COS7
cells. COS7 cells were tran-
siently transfected with TbRI-
HA and treated 48 h later as
described in Fig. 1. Immuno-
precipitation of fractions from
the sucrose gradients was with
a-HA antibodies. Numbers at
the top represent protein size
predicted by size markers in-
cluded in the run. Similar re-
sults were obtained with un-
tagged TbRI. (A) SDS (0.5%)
was included. (B) No SDS.
Figure 3. Affinity labeling of
wild-type and epitope-tagged
TbRI. COS7 cells were tran-
siently transfected with hu-
man TbRII (lanes 1–3) to-
gether with wild-type TbRI
(lane 1), TbRI-myc (lane 2),
or TbRI-HA (lane 3). Alter-
natively, cells were singly
transfected with TbRI-HA
(lane  4) or with the vector
pcDNA-I (lane 5). Cells were
incubated with 100 pM of
125I–TGF-b1, and bound
ligand was cross-linked to
cell surface receptors. Deter-
gent extracts of the transfected
cells were analyzed by 7.5%
SDS-PAGE and exposed to
an x-ray film. Positions of mo-
lecular weight markers and of TbRI and TbRII are indicated.
Cells that were singly transfected with wild-type TbRI or TbRI-
myc did not show labeling above the background of mock-trans-
fected cells, as shown for TbRI-HA (lane 4). Note that under the
transient expression conditions, many cells also express singly ei-
ther TbRI or II, and the relative labeling intensities of the two re-
ceptor types vary between experiments.
for immunoprecipitation and blotting, is depicted in lanes
1 and 2 (Fig. 4 A). The type I receptors appear in two
bands (z59 and 53 kD; Fig. 4 A, lane 1). The upper band is
N-glycosylated TbRI since treatment of the precipitated
receptors with N-glycosidase F led to disappearance of the
59-kD band, leaving only the lower band (Fig. 4 B). The
53-kD band in Fig. 4 A gets somewhat distorted and swept
downward in the coprecipitation lanes because of the pres-
ence of high amounts of the a-HA antibody used for pre-
cipitation (seen in the lowest band). This antibody, unlike
a-myc, runs very close to the lower TbRI band. When the
gels are run under nonreducing conditions (providing bet-
ter separation from the antibody band), this distortion dis-
appears (Fig 4 B). These results demonstrate that TbRI
forms homooligomers that are unaffected by TGF-b1 or
DTT and are stable in the presence of detergents.
Immunofluorescence Copatching Experiments Show 
Ligand-independent TbRI Homodimers on the Surface 
of Live COS7 Cells
The experiments described in the former sections suggest
that TbRI forms dimer-sized complexes and that at least
some of them are caused by homooligomer formation. To
measure the TbRI oligomeric structure at the native cell
membrane, we performed immunofluorescence copatch-
ing studies (for method description see Methods and refer-
ence 12). These studies have the advantage that they are
performed on live cells (without any possible interference
by detergents), measure the bulk of cell surface receptors
on coexpressing cells only, and supply a semiquantitative
measure for oligomer size. In this method, a tagged recep-
tor at the surface of live, unfixed cells is forced into
patches by a double layer of bivalent IgGs. The second re-
ceptor, which carries a different tag, is labeled by antibod-
ies coupled to another fluorophore. The samples are thenThe Journal of Cell Biology, Volume 140, 1998 772
examined to explore whether the second receptor is swept
into the same micropatches or whether the two receptors
congregate in separate patches. The experiment is per-
formed in the cold to avoid internalization. If the two fluo-
rophores used are Cy3 (red emission) and fluorescein
(green emission), then mutual patches appear yellow,
while separate patches are either red or green. It is there-
fore possible to count the percentage of mutual and of sep-
arate patches, thus obtaining a semiquantitative determi-
nation of the level of complex formation and of complex
size (12). It should be noted that the tags (HA and myc)
and antibodies used in the current studies do not mediate
receptor complex formation or nonspecific sweeping into
mutual patches since similar experiments using the same
tags and antibodies did not show copatching between
TbRII and TbRIII (12).
COS7 cells cotransfected with TbRI-HA and TbRI-myc
were subjected to successive incubations with different an-
tibodies to mediate patching and fluorescent labeling of
the tagged receptors, as specified under Materials and
Methods. Typical results are shown in Fig. 5. The labeling
procedure is fully specific, as can be seen in the inset of
Fig. 5 A , showing control cells singly transfected with
TbRI-myc and subjected to the same labeling procedure;
the cells exhibit Cy3 labeling and almost no fluorescein la-
beling, which would be associated with TbRI-HA. In all
cells expressing both TbRI-myc and TbRI-HA, z50% of
the patches were yellow. This indicates that the majority of
TbRI at the cell surface resides in dimers. Statistically, this
is the percentage expected to reside in mutual complexes
in the case of a dimer since only half of the dimers would
carry two different tags (see Discussion). Preincubation
with ligand (Fig. 5, B and D) or DTT (Fig. 5, C and D) did
not alter the percentage of mutual (yellow) patches
formed by the antibodies. It should be noted that 50% co-
patching is not a pattern that is commonly observed in
such experiments; thus, no copatching was detected for co-
expressed TbRII and III (12), and only a low percentage
of copatching is observed for TbRI/TbRII in the absence
of ligand (Wells, R.G., L. Gilboa, Y.I. Henis, and H.F. Lo-
dish, manuscript in preparation). The results presented in
Fig. 5 suggest that all (or most of) the type I receptors appear
as ligand-independent dimers on the surface of live cells and
that this structure is not altered by preincubation with DTT.
TbRII Forms Homodimers in the ER
Homooligomerization of TbRII might have an important
role in TGF-b signal transduction. We have previously
used immunofluorescence copatching to show that TbRII
forms small homooligomers on the surface of live COS7
cells (12), similar to TbRI (Fig. 5). To determine whether
TbRI homooligomerization occurs in the ER, we per-
formed velocity centrifugation experiments with metaboli-
cally labeled, Endo H–sensitive type II receptors. The ex-
periments used L6 cells as described above for TbRI,
except that a shorter labeling pulse (15 min) was required
to give a TbRII population entirely sensitive to Endo H
(Fig. 6 A; reference 41). Velocity centrifugation of TbRII
from cells lysed and run in the presence of 0.5% SDS
yielded a peak at fractions 4–6 (Fig. 6, B and D), consistent
with a monomeric TbRII. Receptors from lysates lacking
SDS migrated with a peak at 150 kD (Fig. 6, C and D),
consistent with the ER form being a dimer. Metabolically
labeled Endo H–resistant receptor, measured after a 2 h
chase, migrated at the same point (data not shown), con-
sistent with our immunofluorescence copatching experi-
ments in COS7 cells (12). Similar results were obtained with
COS7 cells transiently expressing TbRII (tagged or un-
tagged) as well as with Mv1Lu (not shown), confirming
that dimerization of TbRII is not cell type specific. These
findings show that the type II receptors form homodimers
in the ER, which are then transported, presumably in this
form, to the cell surface.
The Ectodomains of TbRII and TbRI Are Monomeric, 
but TGF-b1 Can Induce Dimerization of II-SF
To determine whether the ectodomain of either signaling
Figure 4. Coimmunoprecipitation of TbRI-myc with TbRI-HA.
COS7 cells were transiently transfected with TbRI-myc (IM),
TbRI-HA (IH), or both (IM1IH), as indicated at the bottom of
each lane. Immunoprecipitation was either with a-myc or a-HA,
as indicated at the top of the gel. Blotting was always with a-myc,
followed by biotinylated GaM, streptavidin–horseradish peroxi-
dase, and ECL. All lanes were loaded with immunoprecipitates
derived from the same amounts of cell lysates (three 10-cm
dishes), except where both immunoprecipitation and blotting
were with a-myc (1/3 of the above lysate in A, lane 1; 1/18 in A,
lane 2 and in B, lane 1). (A) Effects of ligand and/or DTT treat-
ment. The gels were run under reducing conditions. In lanes 6
and 8, the cells were preincubated with 250 pM TGF-b1 (2 h,
48C). In lanes 7 and 8, the cells were pre-treated with DTT (see
Materials and Methods). TbRI appears in two bands, around 59
and 53 kD. The nonspecific band at the bottom of lanes 3–8 is a
component of the a-HA antibodies used for the immunoprecipi-
tation in these lanes (see text). (B) Effect of N-glycosidase F. The
59-kD band collapses to 53 kD, indicating that it represents
N-glycosylated receptors. The immunoprecipitates were treated
with N-glycosidase F as described under Materials and Methods.
The gel was run under nonreducing conditions. In lane 3, the cells
were preincubated with 250 pM TGF-b1. The band seen at 62 kD
under these conditions is a nonspecific band. (The specific 59-kD
band disappears).Gilboa et al. Homodimerization of Types I and II TGF-b Receptors 773
receptor is responsible for the homodimerization we have
observed, we performed sucrose gradient velocity centrif-
ugation studies on the secreted ectodomains of both re-
ceptors. The soluble exoplasmic domain of TbRII is effi-
ciently secreted and has binding characteristics equivalent
to the full-length receptor (24). I-SF is also efficiently se-
creted, suggesting that it is correctly folded; however, it
cannot be cross-linked to ligand in the presence or absence
of II-SF and likely requires transmembrane and cytoplas-
mic domains for full interaction with the type II receptor
and for ligand binding (Wells, R.G., L. Gilboa, Y.I. Henis,
and H.F. Lodish, manuscript in preparation). COS7 cells
were transfected with a plasmid carrying an epitope-
tagged form of the soluble type II receptor (II-SF), and the
media from metabolically labeled cells were separated on
detergent-free sucrose gradients. In the absence of ligand,
II-SF peaked at fractions 3–4 (Fig. 7, A and C), predicted
by size markers to be 20 kD, consistent with a monomer.
The truncated receptor has complex and heterogeneous
N-linked glycosylation, accounting for the multiple labeled
bands. The same receptor, when collected from the media
of unlabeled cells and cross-linked to 125I–TGF-b1, mi-
grated as a 60–65-kD protein (Fig. 7, B and C), consistent
with a dimeric receptor bound to the ligand. This dimer-
ization did not occur if detergent (1% Triton X-100) was
added (not shown).
Analogous experiments were conducted on the soluble
form of TbRI (I-SF), described under Materials and Meth-
ods. The results are depicted in Fig. 8. Metabolically la-
beled I-SF migrated with a peak at fractions 3–6 (Fig. 8),
consistent with a monomer of molecular mass around 24 kD.
The broad peak suggests that some I-SF migrated faster,
and there could be some I-SF dimers present. These re-
sults demonstrate that the exoplasmic domains of both
TbRI and TbRII are mainly monomeric and are not suffi-
cient for dimerization by themselves. II-SF, however, can
form dimers upon TGF-b1 binding.
Discussion
TGF-b elicits a broad spectrum of effects, ranging from
control of cell growth and extracellular matrix composi-
tion to differentiation and cell death (37). TGF-b signal
transduction requires two cell surface receptors, TbRI and
TbRII, which are serine-threonine kinases (9, 24). A sub-
stantial amount of evidence attests to interactions between
TbRI and TbRII upon ligand binding (3, 7, 27, 43, 44).
Homomeric interactions of TGF-b receptors, however,
have not been investigated in detail, especially for TbRI.
Although there are clear indications that homomeric in-
Figure 5. Copatching of epi-
tope-tagged TbRI on the
surface of live cells. COS7 cells
were transiently cotransfected
with TbRI-myc and TbRI-HA
(A–D) or with TbRI-myc
alone (A, inset). They were
labeled in the cold consecu-
tively by a series of antibod-
ies to mediate patching and
fluorescent labeling, as de-
scribed under Materials and
Methods. After this labeling
procedure, TbRI-myc is la-
beled by Cy3 (red), TbRI-HA
by FITC (green), and patches
containing both tags are yel-
low. The labeling specificity
is demonstrated by the exclu-
sive labeling with Cy3 (red)
of cells expressing only TbRI-
myc (A, inset) and by the ex-
istence of separately labeled
patches (only red or only
green) in the coexpressing
cells. For each experiment,
the patches on 20–30 cells
were counted on the com-
puter screen to determine the
percentage of double-labeled
(yellow) patches. Flat cell re-
gions were selected for count-
ing, avoiding the region of the
nucleus that is out of focus and contains more nonspecific staining. The percentage of copatching was 46 6 5% in all cases except for the
control. (A) No DTT treatment, no preincubation with ligand. (Inset) Transfection with TbRI-myc only. (B) Incubation with 250 pM
TGF-b1; the ligand was added together with the normal goat IgG preincubation and kept in during all successive incubations. (C)
DTT-treated cells, no ligand. Pretreatment with DTT was done as described under Materials and Methods, before incubations with the
antibodies. (D) DTT-treated cells, incubation with 250 pM TGF-b1. Bars, 20 mm. The Journal of Cell Biology, Volume 140, 1998 774
teractions of type I and type II TGF-b receptors are im-
portant functionally for signal transduction and regulation,
there has thus far been no physical evidence for TbRI ho-
mooligomerization, and the cellular site of TbRII homo-
oligomerization is not known (6, 12, 27, 28, 40). In the cur-
rent studies, we combined several complementary approaches
to investigate this issue: (a) sedimentation velocity studies
to determine the size of metabolically labeled receptor
complexes; (b) coimmunoprecipitation experiments on co-
expressed, differentially tagged forms of TbRI to explore
homooligomer formation; and (c) immunofluorescence co-
patching studies on cells coexpressing differentially tagged
TbRI forms to establish the existence of receptor ho-
modimers at the surface of intact cells.
Sedimentation velocity experiments on metabolically la-
beled TbRI demonstrated that the receptors migrate as a
complex whose size corresponds to a dimer. This complex
was observed in the ER of several cell types, from natu-
rally expressing L6 (Fig. 1) or Mv1Lu cells to transiently
expressing COS7 cells (Fig. 2). This indicates that the
dimer-sized complex formed is not affected by the level of
expression. The fact that the complex size fits a TbRI
dimer does not necessarily point to the existence of such
dimers since some other cellular protein of a similar size
can be associated with the receptor. This issue can be re-
solved by the use of other methods (coimmunoprecipita-
tion and immunofluorescence copatching) to demonstrate
that TbRI does indeed form homodimers and to establish
Figure 6. The type II receptor forms homodimers in the ER. L6
cells were pulse-labeled with 35S-Express for 15 min, chilled, ly-
sed with (B) or without (C) 0.5% SDS, and loaded on sucrose
gradients with (B) or without (C) 0.5% SDS, as in Fig. 1. D is a
graphic representation of the data as in Fig. 1. Endo H digestion
of control material (A), labeled similarly, confirms that all la-
beled receptor is in the ER form (Endo H sensitive).
Figure 7. The ectodomain of TbRII is a monomer and dimerizes
upon TGF-b1 binding. (A) COS7 cells were transfected with II-SF.
48 h after transfection, they were incubated in starvation medium
and labeled with 35S-Express, and the media collected from the
cells were concentrated and centrifuged on 5–15% sucrose gradi-
ents without detergent (see Materials and Methods). Fractions
were immunoprecipitated with a-HA, and immunoprecipitates
were analyzed by SDS-PAGE. (B) Unlabeled media from trans-
fected COS7 cells were collected and cross-linked to iodinated
TGF-b1, as described under Materials and Methods. Samples
were loaded on sucrose gradients and processed as for A. (C) A
graphical representation of the quantitation of bands, as for Figs.
1 and 6.Gilboa et al. Homodimerization of Types I and II TGF-b Receptors 775
independently the existence of TbRI dimers at the cell
surface. The latter experiments require the expression of
epitope-tagged receptors at levels high enough for good
fluorescence visualization, and they were therefore per-
formed in COS7 cells. The use of the overexpressing COS
cells is justified in view of the similar complex size found in
centrifugation studies for TbRI expressed transiently in
COS cells or naturally in the other cell types. Further-
more, similar results were obtained in the copatching stud-
ies on COS7 cells expressing either high (z200,000 recep-
tors/cell at the surface) or low (z20,000) receptor levels
(determined as described in reference 12).
The coimmunoprecipitation studies (Fig. 4) using tagged
TGF-b type I receptors clearly demonstrate physical asso-
ciation between TbRI polypeptides. Thus, the complexes
formed are relatively stable and withstand, at least par-
tially, the detergent solubilization and immunoprecipita-
tion conditions. Together with the centrifugation velocity
studies, which point to a dimer-sized complex, these re-
sults suggest that the complex is indeed a homodimer of
TbRI.
Coimmunoprecipitation experiments do not provide a
measure for the percentage of receptors that reside in oli-
gomers since only part of the cell population (z40%, as
determined by immunofluorescence) coexpresses the two
differently tagged receptors. Immunofluorescence copatch-
ing studies circumvent this problem by selecting only coex-
pressing cells for analysis; they also provide an independent
means to determine the size of the receptor oligomers and,
most importantly, do so at the surface of live cells. By co-
expressing HA- and myc-tagged TbRI, we have observed
that z50% of the patches were dyed yellow (Fig. 5), im-
plying that the majority of TbRI at the surface of COS7
cells is homodimeric. The reasoning is as follows: For
monomers, each type of tagged receptor would be swept
into separate patches by the respective antibody, yielding
no copatching. In the case of a dimer, only half of the
dimers would be composed of receptors carrying different
tags; these will be swept mostly into copatches, while the
great majority of uniformly tagged dimers will reside in ei-
ther green or red patches. For trimers and tetramers, the
expected percentage of complexes carrying different tags
is 75 and 87.5%, respectively. Clearly, the results of the co-
patching experiments are in good agreement with the re-
ceptors being dimeric. They provide an independent proof
for the homodimeric nature of the dimer-sized complex
observed in the centrifugation experiments.
The copatching experiments, as well as the coimmuno-
precipitation studies, show that TbRI dimers are unaf-
fected by the presence of TGF-b1 (Figs. 4 and 5); this is
not surprising since TbRI does not bind TGF-b1 in the ab-
sence of TbRII. Interestingly, the dimeric structure of
TbRI is not disrupted by pretreatment of the cells with
DTT under conditions known to eliminate TGF-b1 bind-
ing to these receptors (Figs. 4 and 5). These findings dem-
onstrate that the homooligomeric complex of the type I re-
ceptors can withstand whatever structural alteration is
mediated by the DTT treatment, and which interferes with
the ability of TbRI to be cross-linked to TGF-b1 in the
presence of TbRII (reference 4; Rodriguez, C., R. Lin,
P.E. Scherer, and H.F. Lodish, unpublished results).
Sedimentation velocity studies analogous to those per-
formed on TbRI were conducted on TbRII (Fig. 6). These
experiments establish that TbRII appears in dimer-sized
complexes, which are formed in the ER. Together with
previous studies using immunofluorescence copatching
(12) and coimmunoprecipitation (6, 12), which demon-
strate that TbRII chains interact with each other, we can
conclude that TbRII appears both in the ER and at the
cell surface as a dimer. The copatching studies (12) indi-
cate that the dimeric nature of TbRII is not altered after
TGF-b1 binding. Moreover, the inherent tendency of
TbRII to form dimers is independent of expression level,
as indicated by the similar results obtained in sedimenta-
tion velocity studies performed on naturally expressing
cell lines and on overexpressing COS cells.
To explore the role of the exoplasmic domain in pro-
moting homodimerization, the soluble exoplasmic do-
mains of TbRI and TbRII secreted by COS7 cells were an-
alyzed by sedimentation velocity experiments (Figs. 7 and 8).
In both cases, the receptors migrated primarily as mono-
mers, indicating that these domains are insufficient to pro-
mote dimerization of either receptor. TGF-b1 induced
dimerization of II-SF (Fig. 7), which binds ligand (24), in
agreement with a report that TGF-b2 and TGF-b3 also
promote dimerization of the ectodomain (20). The ligand-
mediated homomeric interactions of II-SF, however, are
disrupted by the presence of nonionic detergent, indicat-
ing that they are significantly weaker than in wild-type
Figure 8. The ectodomain of TbRI is monomeric. (A) COS7 cells
were transfected with I-SF and metabolically labeled, and the
media collected from the cells were centrifuged on 5–15% su-
crose gradients without detergent as described in Fig. 7 A. Immu-
noprecipitation and SDS-PAGE were as in Fig. 7. (B) Graphical
representation of the quantified bands seen in A.The Journal of Cell Biology, Volume 140, 1998 776
TbRII (data not shown). Accordingly, the intact TbRII is
dimeric in the absence of ligand and does not require
ligand binding for dimerization. An immediate conclusion
is that the cytoplasmic and/or transmembrane domains of
TbRII must have a major contribution to the homomeric
interactions. This conclusion is in accord with the report
(6) that the cytoplasmic domains of TbRII overexpressed
in 293 cells can form homooligomers. There is, however,
evidence that the ectodomains of both receptors also con-
tribute to the homomeric interactions since chimeras com-
posed of the cytoplasmic and transmembrane regions of
TbRI or II and the ectodomain of the Epo receptor re-
quired dimerization by Epo to interact (27, 28). Taken to-
gether, it seems likely that several domains scattered
throughout the receptors contribute to the homomeric in-
teractions. In the case of TbRII, it appears that ligand bind-
ing can enhance the interactions between the ectodomains.
In conclusion, we have combined several methods to
characterize homooligomer formation of TbRI and TbRII.
The findings demonstrate that both receptors exist as ho-
modimers that form in the ER and persist at the cell sur-
face. The roles of homooligomerization and its involve-
ment in the mechanism(s) of TGF-b signaling should be
further explored. It appears, however, that for TbRI the
homodimerization has a critical role in signal transduction
(27, 40), and for TbRII it is involved in modulating signal-
ing (28). The variety of biological responses mediated by
TGF-b ligands raises the possibility that an intricate equi-
librium between various homo- and heterocomplexes,
which can be affected by the binding of various ligands,
plays a role in regulating those responses.
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